Literature DB >> 15182407

The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion.

J Curtis Nickel1, Fred Saad.   

Abstract

The 2003 American Urological Association (AUA) guideline on management of benign prostatic hyperplasia (BPH) was released at the AUA annual meeting in Chicago, April 2003 and the diagnosis and treatment recommendations were published later in 2003. It is likely that the 2003 AUA guideline on the management of BPH will have a profound effect on clinical urologic practice in the USA, but its influence on Canadian urological practice will be different because of our socialized medical system, manpower issues, availability of expensive technology and our unique Canadian perspective. The authors review the 2003 AUA guideline on the management of BPH and based on a perspective obtained from recent publications, consensus/consultant meetings, focus groups and anecdotal experience, attempt to put the recommendations into Canadian context. We conclude that the 2003 AUA guideline for the management of BPH is an important document that should be studied, evaluated and understood by Canadian urologists. Although our perspective is clearly different than our US colleagues, it is likely that the guideline will influence the management of BPH in Canada.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182407

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  10 in total

1.  2010 Update: Guidelines for the management of benign prostatic hyperplasia.

Authors:  J Curtis Nickel; Carlos E Méndez-Probst; Thomas F Whelan; Ryan F Paterson; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

2.  Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update.

Authors:  J Curtis Nickel; Lorne Aaron; Jack Barkin; Dean Elterman; Mahmoud Nachabé; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2018-10       Impact factor: 1.862

3.  UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.

Authors:  Dean Elterman; Mélanie Aubé-Peterkin; Howard Evans; Hazem Elmansy; Malek Meskawi; Kevin C Zorn; Naeem Bhojani
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

4.  The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians.

Authors:  Neal Shore; Barrett Cowan
Journal:  Ther Adv Chronic Dis       Date:  2011-11       Impact factor: 5.091

5.  Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-08-01

6.  The Canadian Benign Prostatic Hyperplasia Audit Study (CanBas).

Authors:  J Curtis Nickel; Joe Downey; Francois Bénard; Michael Chetner; John Grantmyre; Alan So; Paul Whelan
Journal:  Can Urol Assoc J       Date:  2008-08       Impact factor: 1.862

7.  Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners.

Authors:  Takashi Fukagai; Kunitaka Maruyama; Masakazu Nagata; Masashi Morita; Michio Naoe; Hideki Yoshida
Journal:  Int J Urol       Date:  2007-05       Impact factor: 3.369

8.  Prostatic artery embolization for giant prostatic hyperplasia: a single-center experience.

Authors:  André Moreira de Assis; Airton Mota Moreira; Francisco Cesar Carnevale; José Ramón Lanz-Luces
Journal:  Radiol Bras       Date:  2021 Jul-Aug

9.  Patterns in the diagnosis and management of benign prostatic hyperplasia in a country that does not have country-specific clinical practice guidelines.

Authors:  Jae-Seung Paick; Soo Woong Kim; Ja Hyeon Ku
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

10.  Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs.

Authors:  Xifeng Sun; Wei Guan; Haoran Liu; Kun Tang; Libin Yan; Yangjun Zhang; Jin Zeng; Zhiqiang Chen; Hua Xu; Zhangqun Ye
Journal:  BMC Urol       Date:  2018-05-03       Impact factor: 2.264

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.